HC Wainwright Reaffirms Neutral Rating for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports.

LPTX has been the subject of a number of other research reports. Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Stock Performance

Leap Therapeutics stock opened at $0.45 on Thursday. The company’s fifty day moving average price is $0.83 and its 200 day moving average price is $2.21. The stock has a market capitalization of $17.38 million, a P/E ratio of -0.23 and a beta of 0.35. Leap Therapeutics has a 1 year low of $0.39 and a 1 year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Wednesday, March 26th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Sell-side analysts predict that Leap Therapeutics will post -1.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new stake in Leap Therapeutics in the 4th quarter valued at $4,025,000. J. Goldman & Co LP purchased a new stake in shares of Leap Therapeutics in the fourth quarter valued at about $194,000. Jane Street Group LLC acquired a new stake in Leap Therapeutics during the fourth quarter worth about $107,000. Dauntless Investment Group LLC purchased a new position in Leap Therapeutics during the fourth quarter worth about $144,000. Finally, Gilead Sciences Inc. acquired a new position in Leap Therapeutics in the 4th quarter valued at about $15,293,000. 30.46% of the stock is currently owned by institutional investors and hedge funds.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.